TickerTalks
Browse all tickers →
TickerTalks›$EDSA
EDEDSA

Edesa Biotech, Inc.

$EDSA·$68M·Biotechnology·Healthcare
$6.60-1.8%YTD+355.2%1Y+178.5%
Mentions · last 7 days
2026-07-10: 5 posts2026-07-11: 6 posts2026-07-12: 9 posts2026-07-13: 15 posts2026-07-14: 10 posts2026-07-15: 15 posts2026-07-16: 10 posts70+15%
Price updated 4h ago·X counts updated 1d ago
EDEDSA
$EDSAEdesa Biotech, Inc.
$6.60-1.79%70 posts+15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $EDSA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Edesa Biotech up 374% YTD on paridiprubart AKI data — small-cap CEO-led $3.5M PIPE closed.

Edesa Biotech is a Canadian small-cap biotech developing paridiprubart — an anti-TLR4 monoclonal antibody targeting inflammatory conditions including acute kidney injury (AKI). The stock is up 374% YTD on positive June 5 exploratory AKI data.

  • Revenue is essentially zero — this is a clinical-stage biotech; the equity value depends entirely on paridiprubart clinical progression across AKI and other inflammatory indications.
  • Trades at negative TTM P/E on nominal revenue and -16% FCF yield — the multiple math is meaningless at the $68M market cap.
  • The June 11 $3.5M private placement (729,241 common shares) led by CEO Pardeep Nijhawan and healthcare-focused investors is real strategic-alignment signal; CEO-led PIPEs are the strongest management-conviction signal available for small-cap biotech.
  • The June 5 positive exploratory data for paridiprubart in AKI plus continued European Nephrology Conference presentation activity captures the specific clinical-progress cadence.
  • 52-week position 31st percentile with position vs 200-day MA +45% — the tape has confirmed the momentum but is now digesting after the recent run.

August 14 Q3 earnings is where the paridiprubart story either extends or contracts: specific commentary on continued AKI clinical progression plus any additional Phase 2 initiation is what continues the run; another quarter of minimal disclosure plus further dilution is where the +374% YTD gives back. Real early-stage biotech with real CEO-led PIPE alignment and real AKI data catalyst — the setup rewards continued clinical execution.

What to watch: Aug 14 Q3 earnings — need specific commentary on continued AKI clinical progression and any additional Phase 2 initiation. Another quarter of minimal disclosure plus further dilution is where +374% YTD gives back.

On the calendar: 2026-08-14 — Q3 earnings

sentiment absent

Read the AI verdict + X sentiment for $EDSA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing topical and injectable therapies for inflammatory skin diseases and immune-mediated conditions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $EDSA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $EDSA

Direct beneficiary — Clinical-stage biotech developing topical and injectable therapies for inflammatory skin diseases and immune-mediated conditions; the business model is a direct conduit for the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-108%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-15.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-82.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.49$-0.24-104.2%
Q4 2025Feb 13, 2026$-0.28$-0.280.0%
Q3 2025Dec 12, 2025$-0.32$-0.27-18.5%
Q2 2025Aug 8, 2025$-0.25$-0.26+3.8%
Next earningsFri, Aug 14·consensus EPS $-0.44

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.49$-2.1M
Q1 FY26$0———$-0.28$-2.1M
Q4 FY25$0———$-0.32$-1.8M
Q3 FY25$0———$-0.25$-1.8M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$1.66-$1.75 – -$1.570
FY27$19.0M$19.0M – $19.0M-$1.62-$2.11 – -$1.132
FY28$23.3M$23.3M – $23.3M-$1.72-$2.37 – -$1.072
FY29$70.5M$70.5M – $70.5M-$1.87-$1.87 – -$1.871
FY30$112.0M$112.0M – $112.0M-$0.83-$0.83 – -$0.831

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.30%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-23.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 7.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.055-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMar 5Pardeep NijhawanCEO10.0K sh$39KBuyMar 4Pardeep NijhawanCEO10.0K sh$43KBuyMar 3Pardeep NijhawanCEO10.0K sh$36KBuyMar 2Pardeep NijhawanCEO3.0K sh$6KBuyFeb 27Pardeep NijhawanCEO30.0K sh$67KBuyFeb 26Michael J BrooksPresident2.0K sh$3KBuyFeb 26Pardeep NijhawanCEO20.6K sh$32K
+ 17 other (17 awards) in window

See when $EDSA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3Shelf registrationJul 2S-3
AI summary

Edesa Biotech (Markham, Ontario) filed an S-3 shelf registration for future securities offerings with Lowenstein Sandler as counsel. Routine shelf registration for this clinical-stage Canadian biotech.

SC 13D/AActivist amendmentJun 16SC 13D/A
AI summary

A significant holder filed an amended Schedule 13D on Edesa Biotech Inc. (EDSA) on June 16, 2026. Body unavailable — excerpt contains only the SEC cover-page header without filer name, stake percentage, or amended investment intent.

8-KMaterial agreementJun 118-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

Edesa Biotech, Inc. entered into a Securities Purchase Agreement on June 10, 2026, for a ~$3.5 million private placement of 729,241 common shares closing on or about June 15, 2026. Most investors paid $4.69 per share; the CEO paid $5.21 per share (above the general investor price). Proceeds will fund the continued advancement of the company's vitiligo program (drug candidate paridiprubart) and general working capital. A Registration Rights Agreement requires Edesa to file a resale registration statement within 45 days of closing. The raise is a small capital injection — modest dilution — intended to extend runway for a single clinical-stage asset.

8-KOfficer or director changeMay 298-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

EDSA (EDSA) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on the election of directors, an advisory say-on-pay resolution, an equity incentive plan. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KOfficer or director changeMay 158-K — Item 5.02: Officer or director change
AI summary

Edesa Biotech, Inc. (EDSA) filed an 8-K on May 13, 2026 disclosing a personnel change (Item 5.02). Edesa Biotech is a Markham, Ontario-based clinical-stage biopharmaceutical company listed on Nasdaq. The excerpt does not identify the departing or incoming executive; officer changes at a clinical-stage biotech can significantly affect development strategy and investor confidence.

SC 13D/AActivist amendmentMar 2SC 13D/A
SC 13D/AActivist amendmentMar 2SC 13D/A
+ 21 other (9 13Gs · 2 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investorsglobenewswire.com·37d agoEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injuryglobenewswire.com·43d agoEdesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conferenceglobenewswire.com·60d agoEdesa Biotech Reports Fiscal 2nd Quarter 2026 Resultsglobenewswire.com·64d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · last 7 days

No standout posts about $EDSA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport